Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Rossi

Showing results (441-450 of 504) with videos related to

Pageof 51
Sort By:
Leukemia|June 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Candida Vitale, Diana Giannarelli, et al.
Hematological Oncology|October 3, 2022
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemiaRiccardo Moia, Riccardo Dondolin, Maria Stefania De Propris, et al.
Haematologica|September 21, 2019
<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Davide Rossi, Andrea Rinaldi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2018
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell LymphomaDavid M Kurtz, Florian Scherer, Michael C Jin, et al.
Blood|February 2, 2020
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expressionErika Tissino, Federico Pozzo, Dania Benedetti, et al.
American Journal of Hematology|April 17, 2023
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemiaFortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasAlberto J Arribas, Francesca Guidetti, Eleonora Cannas, et al.
Hematological Oncology|June 22, 2025
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)Annarita Conconi, Andrea Janikova, Barbara Vannata, et al.
Blood|December 18, 2015
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutationsViktor Ljungström, Diego Cortese, Emma Young, et al.
Pageof 51

Showing results (441-450 of 504) with videos related to

Sort By:
Pageof 51
Leukemia|June 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Candida Vitale, Diana Giannarelli, et al.
Hematological Oncology|October 3, 2022
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemiaRiccardo Moia, Riccardo Dondolin, Maria Stefania De Propris, et al.
Haematologica|September 21, 2019
<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Davide Rossi, Andrea Rinaldi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2018
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell LymphomaDavid M Kurtz, Florian Scherer, Michael C Jin, et al.
Blood|February 2, 2020
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expressionErika Tissino, Federico Pozzo, Dania Benedetti, et al.
American Journal of Hematology|April 17, 2023
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemiaFortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasAlberto J Arribas, Francesca Guidetti, Eleonora Cannas, et al.
Hematological Oncology|June 22, 2025
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)Annarita Conconi, Andrea Janikova, Barbara Vannata, et al.
Blood|December 18, 2015
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutationsViktor Ljungström, Diego Cortese, Emma Young, et al.
Pageof 51